Home › Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease
 

Keywords :   


Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease

2014-11-05 05:46:07| drugdiscoveryonline Home Page

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, recently announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease

Tags: with study eye phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »